This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KRON Kronos Bio (KRON) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Kronos Bio Stock (NASDAQ:KRON) Get Kronos Bio alerts:Sign Up Key Stats Today's Range$0.87▼$0.8850-Day Range$0.67▼$0.8952-Week Range$0.65▼$1.46Volume54,089 shsAverage Volume370,931 shsMarket Capitalization$53.72 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingHold Company Overview Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California. Read More Receive KRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KRON Stock News Headlines$1.8 billion fund is gobbling up Bay Area biotech 'zombies' for cheapJuly 9, 2025 | msn.comKronos Bio Completes Merger with Concentra BiosciencesJune 20, 2025 | tipranks.comShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.October 17 at 2:00 AM | Brownstone Research (Ad)Kronos Bio sends Cambridge lab space back to marketJune 5, 2025 | bizjournals.comKronos Bio Terminates Cambridge Lease AgreementJune 5, 2025 | tipranks.comOrca Bio Appoints Key Executives Including Steve Gavel as Chief Commercial OfficerJune 4, 2025 | finance.yahoo.comKRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRONMay 4, 2025 | businesswire.comConcentra To Acquire Kronos BioMay 3, 2025 | nasdaq.comSee More Headlines KRON Stock Analysis - Frequently Asked Questions How were Kronos Bio's earnings last quarter? Kronos Bio, Inc. (NASDAQ:KRON) announced its quarterly earnings data on Tuesday, March, 18th. The company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.13. The company had revenue of $2.27 million for the quarter, compared to analyst estimates of $1 million. Kronos Bio had a negative trailing twelve-month return on equity of 64.22% and a negative net margin of 701.53%. When did Kronos Bio IPO? Kronos Bio (KRON) raised $175 million in an initial public offering on Friday, October 9th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO. What other stocks do shareholders of Kronos Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Taseko Mines (TGB), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD). Company Calendar Last Earnings3/18/2025Today10/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRON CIK1741830 Webkronosbio.com Phone650-781-5200FaxN/AEmployees100Year Founded2017Price Target and Rating Average Price Target for Kronos Bio$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside+13.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$86.08 million Net Margins-701.53% Pretax Margin-701.53% Return on Equity-64.22% Return on Assets-47.17% Debt Debt-to-Equity RatioN/A Current Ratio12.93 Quick Ratio12.93 Sales & Book Value Annual Sales$9.85 million Price / Sales5.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book0.61Miscellaneous Outstanding Shares61,050,000Free Float46,155,000Market Cap$53.72 million OptionableOptionable Beta1.64 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:KRON) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
